HHS has introduced an interim peptide compounding policy covering six substances, creating new opportunities and raising pharmaceutical safety concerns.
Alembic Pharmaceuticals' USFDA approval strengthens its position in the generic eye drops market through a specialised ophthalmic formulation.
Stroke prevention remains a major challenge even after patients survive an initial ischemic stroke or a high-risk transient ischemic attack (TIA).
Cancer drug price cuts are expected to save patients Rs 3,540 crore annually, improving affordability through revised medicine prices.
Head and neck cancer patients with advanced disease have waited a decade for a new targeted treatment breakthrough after platinum-based chemotherapy.
Dr. Reddy's secures Brazilian regulatory approval for semaglutide, entering a competitive diabetes treatment market with USD 244.6 million in estimated commercial potential.
Alembic Pharma’s Q2 surge highlights a changing growth engine, with US formulations, domestic branded medicines and API operations driving earnings.
Center expands drug import gateways under Rule 43A, aiming to ease pharma logistics, improve cargo movement and reduce clearance delays.
Dr Reddy’s lenacapavir gets USFDA nod for HIV prevention, advancing affordable twice-yearly injections and expanding access across 120 low- and middle-income countries.
Sun Pharma gains CDSCO approval for oral semaglutide tablets, marking its entry into India’s competitive oral GLP-1 market.
.jpg)
, CDSCO.jpg)
